A Safety Study of LY2886721 Multiple Doses in Healthy Subjects

NCT01227252 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: LY2886721
DRUG: Placebo

Sponsor

Eli Lilly and Company